



PRESS RELEASE

PACKETEER HELPS CANCER RESEARCH UK IMPROVE NETWORK PERFORMANCE

PacketShaper intelligent application acceleration solution allows charity to prioritise and optimise business critical traffic

London, UK, 8 January 2007 – Packeteer[®], Inc. (NASDAQ: PKTR), the global leader in WAN application optimisation, has announced that Cancer Research UK, the world's leading independent organisation dedicated to cancer research, has deployed PacketShaper[®] technology to improve the application performance across its network. Packeteer's line of WAN optimisation products provide classification for more than 600 applications to provide intelligent acceleration for all business critical traffic.

As with any large organisation, Cancer Research UK had large amounts of business critical and non-critical material flying across the network everyday. The company was struggling to prioritise business critical information and in addition, the network was straining under the sheer pressure of the volume of material that the 3,000 network users were sending and receiving.

Cancer Research UK first installed a PacketShaper 6500 two years ago when a BT MPLS network was installed across 34 sites in the UK and Northern Ireland. The links were a mix of fixed bandwidth, ADSL and flex circuits which were various bandwidths sitting on 100meg circuits. The flex circuit was unable to flex up to the megabytes required because BT were not rate limiting the traffic, and instead simply dropped off packets to ensure other traffic could pass through as soon as the MB limit was reached.

Despite consultation and testing with BT and attempts to configure Cancer Research UK's core switches to limit the traffic, Cancer Research UK came to the conclusion that the most practical and economical solution would be to purchase a device which would control the traffic from its headquarters.

Taking a 10 meg PacketShaper 6500 already in use at Cancer Research UK, a testing period showed that it was possible to increase traffic from 2MB to 10MB on the 15MB flex circuit coming into headquarters. Packeteer provided a 48meg 6500 appliance so Cancer Research UK could have a more accurate impression of whether the products could really provide the solution it sought. At the end of this period, IT staff came to the conclusion that rather than

outlay to replace the core network switches to provide the rate limiting, the most cost effective solution would be to install the PacketShaper appliance.

Having determined the functionality available, Cancer Research UK soon brought in another PacketShaper 6500 to help control non-business critical activity on the Internet. The PacketShaper allowed IT staff to slow down activity such as MSN and iTunes while enabling more work specific sites to perform optimally. Working with reseller Explico, Cancer Research UK also found that cost savings could be made in other areas, with initial investigations showing an immediate increase in throughput on the fixed 2 meg links from 2MB to 4MB. The ability to use the PacketShaper to prioritise traffic also made VoIP calls across the network possible without having to pay the additional rental required for BT to provide it.

The PacketShaper solutions have allowed Cancer Research UK to effectively double its bandwidth without any of the usual expenditure, whilst also helping to report on the network utilisation and the type of traffic coming across the network.

Jane Swindle at Cancer Research UK said, “The PacketShaper products have meant that end users are now experiencing a network that delivers business critical information quickly and efficiently. One problem we were up against was that a lot of large scientific images travel around the network causing bottlenecks. One of the advantages of using Packeteer is that it allows us to identify such traffic and trickle it out slowly, optimising other traffic to move across the network without delays.”

Swindle continued, “Such is the success of the PacketShaper that we are now looking to install PacketShaper 1400s or 1700s on some of our remote sites in the UK both to improve the bandwidth available and enable VOIP across the WAN. Our goal is to bring the cost savings and efficiency of this solution to the whole company.”

About Cancer Research UK

Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.

- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.

- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 020 7009 8820 or visit www.cancerresearchuk.org

About Packeteer

Packeteer, Inc. (NASDAQ: PKTR) is the global market leader in high-performance, intelligent WAN Application Delivery. With over 55,000 systems deployed at more than 7,000 customers worldwide, Packeteer solutions increase WAN capacity and accelerate and ensure predictable network application performance for all users anywhere in the distributed enterprise. By automatically classifying over 600 applications and utilizing the most comprehensive network monitoring, QoS, WAFS and acceleration technologies, Packeteer solutions improve business operational efficiency and provide customers with a rapid return on investment. For more information, contact Packeteer at +1 408 873-4400 or visit the company's web site at www.packeteer.com.

###

Safe Harbour Clause

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, including statements regarding Packeteer's expectations, beliefs, intentions or strategies regarding the future. Forward-looking statements include express or implied statements regarding future revenues and profitability, spending levels by existing and prospective customers, new product development, liquidity and macro economic conditions. All forward-looking statements included in this press release are based upon information available to Packeteer as of the date hereof. Packeteer assumes no obligation to update any such forward-looking statements. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from those projected. Actual results may differ materially due to a number of factors including the perceived need for our products, our ability to convince potential customers of our value proposition, the costs of competitive solutions, continued capital spending by prospective customers and macro economic conditions. These and other risks relating to Packeteer's business are set forth in Packeteer's Form 10-K filed with the Securities and Exchange Commission on March 21, 2003, and Packeteer's Form 10-Qs and other reports filed from time to time with the Securities and Exchange Commission.

Press contacts

Andy Chatterton or Ryan Whelan
Johnson King PR
020 7457 7799
PacketeerTeam@johnsonking.co.uk